Upjohn/Rorer
Executive Summary
Marketing agreement expanded, giving Upjohn certain marketing rights outside the U.S. to Rorer's cardioselective beta blocker Selectol (celiprolol) and Frumil co-marketing rights in West Germany, France, Italy and Spain. The two companies recently agreed to co-promote Ansaid and celiprolol in the U.S. ("The Pink Sheet" July 24, T&G-5).
You may also be interested in...
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.
Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims
Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.